Dedicated to Developing New Treatment Options Safely and Responsibly
At FibroGen, we are dedicated to advancing first-in-class medicines that have the potential to provide new and effective treatment options to the patients who need them.
Before a new treatment can be made widely available, it must go through rigorous testing involving extensive preclinical and clinical studies. These studies are carefully conducted within guidelines set by the U.S. Food and Drug Administration (FDA) and corresponding regulatory authorities outside the U.S. The purpose of clinical trials is to evaluate the safety and effectiveness of promising new therapeutics. Patients who participate in clinical trials may gain access to investigational treatments before they are widely available, and play an important role in helping researchers and clinicians answer key questions about potential new products. Given the COVID-19 pandemic, we remain focused on accelerating enrollment of all of our ongoing clinical trials while ensuring patient safety.
Roxadustat is progressing through a global Phase 3 clinical development program for the treatment of anemia in chronic kidney disease, and is in Phase 3 development in the U.S., Europe, and China for treatment of anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia (CIA).
Pamrevlumab is being evaluated in Phase 3 clinical studies for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF).
We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. Please review the information found on this website as well as at Should you locate a clinical study with a participating site that you are interested in, you or your physician may contact that site directly to request more information about enrollment.
In exceptional cases, when patient participation in a clinical trial is not possible, and there are no other therapies available to treat the patient’s disease or condition, the patient’s physician may request access to one of our investigational drugs on humanitarian grounds. These requests are sometimes referred to as “expanded access” or “compassionate use”, though other terms may be used for the same request. For our policy on expanded access or for more information, please contact us here.